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Abstract 
 
Background: The prevalence of true asymptomatic COVID-19 cases is critical to policy makers 
considering the effectiveness of mitigation measures against the SARS-CoV-2 pandemic. We aimed 
to synthesize all available research on the asymptomatic rates and transmission rates where possible.  
 
Methods: We searched PubMed, Embase, Cochrane COVID-19 trials, and European PMC for pre-
print platforms such as MedRxiv. We included primary studies reporting on asymptomatic 
prevalence where: (a) the sample frame includes at-risk population, and (b) there was sufficiently 
long follow up to identify pre-symptomatic cases. Meta-analysis used fixed effect and random effects 
models. 
 
Results: We screened 571 articles and included five low risk-of-bias studies from three countries 
(China (2), USA (2), Italy (1)) that tested 9,242 at-risk people, of which 413 were positive and 65 
were asymptomatic. Diagnosis in all studies was confirmed using a RT-qPCR test. The proportion of 
asymptomatic cases ranged from 6% to 41%. Meta-analysis (fixed effect) found that the proportion 
of asymptomatic cases was 16% (95% CI: 12% - 20%) overall; higher in non-aged care 19% (15% - 
24%), and lower in long-term aged care 8% (4% - 14%). Two studies provided direct evidence of 
forward transmission of the infection by asymptomatic cases but suggested lower rates than 
symptomatic cases.  
 
Conclusion: Our estimates of the prevalence of asymptomatic COVID-19 cases are lower than many 
highly publicized studies, but still substantial. Further robust epidemiological evidence is urgently 
needed, including in sub-populations such as children, to better understand the importance of 
asymptomatic cases for driving spread of the pandemic. 
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Introduction  	
Asymptomatic cases of any infection are of considerable concern for public health policies to manage 
epidemics. Such asymptomatic cases complicate the tracking of the epidemic, and prevent reliable 
estimates of transmission, tracing, and tracking strategies for containing an epidemic by isolating and 
quarantining. This has been a significant concern for the current COVID-19 pandemic. Multiple 
reports have quoted the reproduction number to be 3; this is the number of cases estimated to be 
infected by an index case in a susceptible population.1 Some modelling experts doubt this low R0 
could explain the global exponential spread we have observed. Using data from 13 countries they 
have estimated the number could be as high as 15.4 (range 5.5-25.4) if asymptomatic carriers were 
incorporated in the equation.2 
  
The possibility of asymptomatic transmission of COVID-19 cases was first raised by a case report in 
China where a traveler from Wuhan was presumed to have transmitted the infection to 5 other family 
members in other locations while she remained asymptomatic for the entire 21-day follow-up 
period.3 Subsequently a number of other reports confirmed not only the possibility but began 
quantifying the potential proportions. For example, the outbreak on the Diamond Princess cruise 
ship4 demonstrated a significant proportion of asymptomatic cases once widespread testing of those 
on board the ship had been undertaken. A recent review by the Centre for Evidence Based medicine 
in Oxford5 found a range of estimates of asymptomatic COVID19 cases which ranged from 5% to 
80%. However, many of the identified studies were either poorly executed or poorly documented, 
making the validity of these estimates questionable. 
 
We therefore sought to identify all studies that had attempted to estimate the proportion of 
asymptomatic COVID-19 cases, select those with minimal or no bias, and synthesize these to provide 
an overall estimate and potential range. We also aimed to estimate the asymptomatic transmission 
rates if sufficient data were found.      
 
Methods 
 
We conducted a systematic review and a meta-analysis. We searched PROSPERO database to rule 
out existence of a similar review; then on the 8th of April 2020 systematically searched PubMed, 
Embase, Cochrane COVID-19 trials, and European PMC for pre-print platforms such as MedRxiv. 
We did not include government websites in the initial search due to the difficulty in systematically 
searching them, but considered them during full text screening and citation analysis stages. The 
selected search strategy for all databases is presented in Supplement 1.  
 
We restricted publication types to reports of primary data collection released in full (including pre-
prints) with sufficient details to enable a risk of bias assessment. We anticipated cross-sectional 
prevalence surveys with follow up, and cohort studies would be the bulk of eligible reports. No 
restrictions on language were imposed.   
 
We excluded studies for following reasons: unclear sampling frame; no or unclear follow up; no data 
on asymptomatic cases; single case study/small cluster; modelling or simulation studies (but sources 
of real data were checked for possible inclusion); non-SARS-CoV-2 virus study; antiviral treatment 
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studies; study protocols, guidelines, editorials or historical accounts without data to calculate primary 
outcomes. 
 
Participants 
We included studies of people of any age who were at-risk of contracting SARS-CoV-2 virus, 
diagnosed by laboratory-based real time quantitative reverse transcription polymerase chain reaction 
(RT-qPCR) or serological tests to be positive, but remained symptomless throughout the follow up 
period of at least 7 days to distinguish them from pre-symptomatic cases.  
 
Outcomes 
Our primary outcome was proportion of all true SARS-Cov-2 infected people who were completely 
asymptomatic at the time of test and throughout the follow up period, where the denominator 
included all tested individuals in the study sample whose result was positive, and the numerator 
included those who tested positive and had no symptoms. Our secondary outcome was estimate of 
community spread from true asymptomatic cases. 
 
Study selection and screening 
Two authors (OB and MC) independently screened titles, abstracts, and full texts according to 
eligibility criteria. All discrepancies were resolved via group discussion with the other authors. 
Reasons for exclusion were documented for all full text articles deemed ineligible (Supplement 2) - 
see PRISMA diagram (Figure 1).  
 
Data extraction 
Three authors (OB, MC, KB) used a Microsoft Excel form to extract the following information: 1. Methods: study authors, year of publication, country, publication type, duration of study, duration 
of follow-up	2. Participants: sample size, age (mean or median; range), setting (community, province, aged care 
facility, hospital, screening clinic), presence or absence of symptoms, test results. 	3. History of illness and diagnosis: Type of test, numerator, denominator/sampling frame, 
proportion of asymptomatic, mild symptomatic, or symptomatic subjects, and number or 
proportion of people infected by the asymptomatic case.	
 
Case definition: Asymptomatic: confirmed via any testing specified above without report of symptom 
onset for the duration of sufficient follow-up to differentiate from pre-symptomatic cases. Exposure: 
Self-reported and/or documented contact with a confirmed case or potential contact of another pre-
symptomatic person (e.g. came from an endemic area or linked with an infected traveler). The World 
Health Organization (WHO) recommends that “for confirmed asymptomatic cases, the period of 
contact is measured as the 2 days before through the 14 days after the date on which the sample was 
taken which led to confirmation”.6  
 
Risk of bias assessment 
We used a combination of risk of bias tools for prevalence studies7 and diagnostic accuracy8 and 
adapted the key signaling questions on sampling frame, ascertainment of infectious disease status, 
acceptability of methods to identify denominators, case definition of asymptomatic for the numerator, 
and length of follow up, as shown in Table 2 and in Supplement 3 in full. 
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Data analysis 
We estimated the proportion of COVID-19 cases that were asymptomatic for each included study 
population, assuming a binomial distribution and calculating exact Clopper–Pearson confidence 
intervals. We then pooled data from all included studies using (1): fixed effect meta-analysis and (2): 
random effects meta-analysis. All analyses were conducted using SAS 9.4; the FREQ procedure was 
used for individual studies and the fixed effect meta-analysis; the NLMIXED procedure was used for 
the random effects meta-analysis. 
 
We planned to undertake subgroup analysis for age (between studies, and within studies where age 
was reported separately for asymptomatic and symptomatic cases). As only studies deemed to be of 
high quality on items 1 and 2 after risk of bias appraisal were included in the analysis, no sensitivity 
analysis of high versus low quality studies was undertaken.  
 
Results  
 
Five hundred-seventy-one articles were screened for title and abstract and 69 full-text assessed 
(Figure 1). Major reasons for exclusion were inadequate sampling frame and insufficient follow-up 
time to accurately classify the asymptomatic cases. Full list of excluded studies with reasons is 
presented in Supplement 2. Five articles - three published and two pre-prints - from three countries 
(China (2), United States of America (USA) (2), and Italy (1)) that tested 9,242 close contacts of at 
least 740 confirmed COVID-19 cases, of which 413 were positive and 65 were asymptomatic, met 
eligibility criteria for the estimation of the primary outcome.9-13  
 
 
Figure 1. Screening and selection of articles  	
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Their sampling frames were residential aged care facilities (RACF) in USA12,13; a community sample 
of source cases and their close contacts11;  a community screening program of Shenzhen cases and 
their close contacts including hospitalized patients, fever clinics and travelers contacts10 and a whole 
District surveillance program in Italy9. The demographic characteristics (Table 1) indicate that most 
of the tested individuals were adults, with mean age over 70 years in the two RACF studies,12,13 and 
mean over 37 years in the three9-11 community screening programs. The proportions of children and 
young people were reported as 8.2% aged 0-19 years10, 15.8% aged 0-17 years11, and 16.6% aged 0-
20 years9 respectively. (Table 1) 
 	
Diagnosis in all studies was confirmed via RT-qPCR and in one case supplemented with radiological 
evidence.11 Testing intensity varied across settings and in the eligible studies intensity was generally 
over 85% as follows: all contacts regardless of symptoms;10-12	 93% of residents13 and 85.9% of an 
entire town.9 The case definitions for asymptomatic cases usually included self-reported absence of 
fever and cough10,12 in addition to absence of other symptoms,9 self-report supplemented with chart 
abstraction in the RACFs for people with severe cognitive impairment,12,13 or described as 
“asymptomatic throughout” the study period.11 Length of follow-up for monitored individuals in the 
RACF studies was 7 to 19 days;12,13 14 days for the Chinese travelers and their contacts;11 7-14 days 
in the Italian community;9 and 12 days for 95% of all contacts in the Shenzhen community 
surveillance.10 	
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Table	1.	Characteristics	of	included	studies	(n=5)	
Study	ID,	
year	and	
country	
Study	population	
(sampling	frame)	
Sample	size,	
mean	age	
Type	of	
diagnostic	
testing	
Length	of	
follow	up	of	
asymptomatic	
cases	
Outcomes	
Lavezzo	et	
al9	2020	
(Italy)	Preprint	
Majority	of	population	of	Italian	town	of	Vo	following	a	COVID-19	death	on	21	Feb.	Quarantine	measures	were	in	place	from	23	Feb	–	8	Mar.	
N=2,812.	Mean	age	of	cohort	47	yrs,	mean	age	of	cases	58	yrs.	
Nasal	swab,	RT-qPCR	 7-14	days	
Prevalence	and	risk	of	infection,	prevalence	of	asymptomatic	cases,	transmission	rate	
Bi	et	al10	
2020	
(China)		Preprint	
Close	contacts	of	391	confirmed	cases	identified	by	the	Shenzhen	CDC	before	February	9th.	
N=1,286.	Mean	age	of	cohort	37.9	yrs,	mean	age	of	cases	42.5yrs.	
Nasal	swab,	RT-qPCR	 95%	followed	up	for	12+	days	
Proportion	of	asymptomatic,	mild,	moderate	and	severe	cases,	transmission	rate	(secondary	attack	rate),	incubation	period	
Luo	et	al11	
2020	
(China)	Preprint	
Close	contacts	of	347	confirmed	COVID-19	patients	identified	between	January	13	and	March	6,	2020,	in	Guangzhou,	Guangdong	Province,	China.	
N=4,950.	Mean	age	of	cohort	38	yrs,	mean	age	of	cases	44.2	yrs.	
Nasal	swab,	RT-qPCR	 14	days	
Infection	rates,	modes	of	contact,	clinical	characteristics	of	confirmed	cases	and	source	cases,	risk	of	transmission	
Kimball	et	
al12	2020	
(USA)	Published	
Residents,	healthcare	personnel,	and	visitors	of	Long-Term	Care	Facility	following	a	SARS-CoV-2(+)	case	on	1	Mar.	
N=76.	Mean	age	of	cohort	76.8	yrs,	mean	age	of	cases	80.7	yrs.	
Nasal	swab,	RT-qPCR	 7	days	
Prevalence	of	SARS-CoV-2	infections,	rate	of	asymptomatic	cases,	clinical	features	of	COVID-19	among	patients,	transmission	rate	
McMichael	
et	al13	
2020	
(USA)	Published	
Residents	of	Long-Term	Care	Facility	following	a	SARS-CoV-2(+)	case	on	28	Feb.	
N=118.	Mean	age	of	cases	83	yrs.	 Nasal	swab,	RT-qPCR	 ~19	days	
Prevalence	of	SARS-CoV-2	infections,	rate	of	asymptomatic	cases,	clinical	features	of	COVID-19	among	patients			
 	
The proportion of asymptomatic cases in the 5 included studies ranged from 6% (95% CI 3% - 12%) 
in China11 to 41% (95% CI 30% - 53%) in Italy.9 Combining data from all five studies, we estimate 
that 16% of cases were asymptomatic (95% CI: 12% - 20%; fixed effects); for the three non-aged 
care studies: 19% (15% - 24%), and for the two studies of long-term aged care facilities 8% (4% - 
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14%). The corresponding estimated proportions in the random effects meta-analysis (not depicted) 
were: overall 14% (95% CI: 3% - 47%), non-aged care 19% (5% - 50%), and aged care 9% (2% - 
29%). The one study that reported on age-specific proportions of asymptomatic infection, found 
similar proportions across all age groups.9		
		
Figure 2. Fixed effects pooled estimates of proportion of asymptomatic carriers by 
subpopulations. N - positive cases; n - asymptomatic cases. 
 
 
Two studies9,11 reported data on possible community spread from asymptomatic cases. Luo et al 
reported on 2610 close contacts of 186 source cases where severity of disease was known. One new 
case resulted from 305 close contacts of asymptomatic source cases (0.3%), compared to 19 new 
cases from 576 close contacts of mildly symptomatic source cases (3%), and 98 new cases from 1729 
case contacts of moderate, severe or critical source cases (6%). Lavezzo et al reported that of the 8 
new cases identified during the second population survey, the source cases were asymptomatic in 3, 
and unknown in 2. Two studies of the cycle threshold (Ct) from real-time RT-PCR assays both found 
that asymptomatic and symptomatic individuals did not differ on this measure of potential viral 
transmission.9,12  
 
Risk of bias of included studies 
Table 2 summarizes the overall risk of bias assessment of the five included studies (full list of risk of 
bias questions in Supplement 3). All of the studies were evaluated as low risk of bias in majority of 
the categories. Two studies had potential non-response bias for not testing all of the eligible 
participants: 7% (6/82) of participants in Kimball et al study and 14% (463/3275) of the target 
population was not tested in Lavezzo et al study. Two studies in aged-care patients posed an 
additional risk of bias concern because of large proportion who had cognitive impairment who might 
not report symptoms fully. Only one study explicitly stated the asymptomatic case definition they 
adhered to.  
 
 . CC-BY-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted May 15, 2020. .https://doi.org/10.1101/2020.05.10.20097543doi: medRxiv preprint 
	 	 		
8	of	12	
Table 2. Risk of bias in 5 included studies. Green smiley face denotes low risk, yellow straight face 
- unclear risk. 
	
 
Excluded studies  
 
Several well publicized studies did not meet our inclusion criteria. The outbreak on the Diamond 
Princess cruise ship involved 3,711 passengers of whom over 600 acquired COVID-19.4 Many of the 
positive cases were relocated to medical facilities in Japan without details of their clinical 
progression. To correct for the lack of follow-up, Mizumoto and colleagues applied a statistical 
adjustment for the right censoring and estimated that 17.9% (95% CI 15.5% - 20.2%) of positive 
cases were asymptomatic. 
 
An open invitation screening of the Icelandic population suggested around 0.8% of the population 
were SARS-CoV-2 positive, with half classified as (initially) asymptomatic.3 However, as there was 
no follow-up, we cannot separate asymptomatic from pre-symptomatic. Furthermore, the study 
excluded symptomatic people undergoing targeted testing, which impeded an estimate of an overall 
asymptomatic rate. 
 
A study of 215 pregnant women in New York identified 33 SARS-CoV-2 positive women.14 On 
admission to the delivery unit, 4 of the 33 positive cases were symptomatic and 3 became 
symptomatic before postpartum discharge, suggesting an asymptomatic rate of 26/33 (79%). 
However, the 2 days of follow-up was insufficient to meet our inclusion criteria.  
 
A case report of a pre-symptomatic Chinese businessman transmitting COVID-19 to a German 
business partner was also excluded because despite three other people acquiring the infection from 
the affected German source, none of them was asymptomatic at follow-up.15  A 5-day point-
prevalence testing of adults living in homeless shelters in Boston found 147 positive cases of which 
“the majority” had mild or no symptoms.16 We excluded this study, as there was no numeric estimate 
for true asymptomatic, and no follow-up assessment. 
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Two studies examined people repatriated from overseas to their home countries by plane. Neither 
study was clear whether symptomatic people could be included - and if excluded, they would 
overestimate the asymptomatic rates. The study of 565 Japanese citizens repatriated from China,17 
found 13 positives: 4 asymptomatic and 9 symptomatic, based on screening on arrival. The other of 
383 Greek citizens repatriated from UK, Spain, and Turkey18 found 40 asymptomatic positives on 
arrival, 4 of whom later self-reported symptoms. Again, the likely initial exclusion of symptomatic 
people, and the lack of comprehensive follow up would both overestimate the asymptomatic rates. 
 
Discussion 
 
Though the rate of asymptomatic COVID-19 cases has received considerable attention, we could find 
only five studies that provided an adequate sample frame and follow-up to ascertain a valid estimate 
of the proportion of asymptomatic. The combined estimate of the asymptomatic proportion was 16% 
(95% CI 12% - 20%), but with considerable residual uncertainty even with the five studies pooled. 
Aged care facilities appear to give a lower asymptomatic rate though with insufficient data for a firm 
conclusion. Only two of the five studies provided any valid data on transmission rates from 
asymptomatic cases, the larger Chinese study suggesting lower rates of transmission than from 
symptomatic cases.  
 
There are several limitations to our findings. First, our search focused on published and pre-print 
articles, and may have missed some public health reports that are either unpublished or only available 
on organisational websites. Second, the design and reporting of most of the studies had a number of 
important deficits that could impact their inclusion or our estimates. These deficits include the poor 
reporting of the sample frame, the testing and symptom check, and the follow-up processes. Such 
reporting would have been considerably aided by a flow chart of cases (as Lavezzo et al does) of 
identification, testing, and follow-up including missing data. A further important limitation was the 
poor reporting of symptoms, which was often simply dichotomised into symptomatic versus 
asymptomatic without clear definitions and details of possible mild symptoms. The included studies 
did not report sufficient data to examine the impact of age and underlying comorbidities on the 
asymptomatic rate. Finally, all included studies relied on RT-qPCR, hence some cases might have 
been missed due to false negative result.19 If the tests missed more asymptomatic cases, then the true 
prevalence of asymptomatics could be higher than our estimates.  
  
While several previous articles have discussed the research on asymptomatic rates, the only 
systematic attempt we could identify was by the Centre for Evidence Based Medicine in Oxford. 
Their rapid review identified 21 articles with asymptomatic rates that vary between 5% and 80%, 
including three of the five articles eligible for our review.5 However, their rapid review did not 
include a critical appraisal of the article methods nor an attempt to pool the most valid studies. Given 
the importance of this topic to decision-making, an ongoing “living review” is warranted to refine 
estimates as new and better data appear. For example, when it becomes available, the CDC report on 
the 600 cases onboard the Theodore Roosevelt will be important, as reports suggest the initial 
asymptomatic rate was 60% but no follow up details are available.  
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There are still many unanswered questions about asymptomatic cases remain. In four of the studies 
the asymptomatic cases were not retested for RT-qPCR status, and none tested for IgG and IgM 
antibodies. A recent USA seroprevalence  study20 reported that based on antibody testing, the 
infection was potentially more widespread than the inference from the number of confirmed cases. 
With the majority of symptomatic cases developing detectable IgM and IgG antibodies between day 
12 and 14 after disease onset respectively,21 follow-up of asymptomatic cases may need to be 
extended to prevent incorrectly labelling a person as a case or infectious. The estimated sensitivity 
and specificity of IgG and IgM tests and PCR tests may only apply to study populations that exclude 
asymptomatic cases. Without repeated PCR tests and follow-up with antibody tests our infection 
prevention strategies for asymptomatic cases remain uncertain.  
  
Estimates of asymptomatic rate and transmission rate are vital parameters for modelling studies. Our 
findings do not however suggest that up to these proportions of asymptomatic cases drive clusters or 
imply a role in undetected outbreaks. Other unknowns include whether there is a difference in age 
(particularly children vs adults), sex and underlying comorbidities that differentiate asymptomatic 
from pre-symptomatic cases; development of long-term immunity; and whether asymptomatics take 
longer to develop active disease or remain silent.  
  
Clear evidence of a true asymptomatic state has implications for our approach to containment of 
infection and surveillance strategies. For example, if asymptomatic cases are important drivers of 
outbreak, then extensive community surveillance programs will need to include everyone for testing. 
Quarantining all positive RT-qPCR asymptomatic cases have cost benefit implications for authorities 
and the individual. Quarantining may even be unnecessary and extensive immunological follow-up of 
asymptomatic cases will determine whether wearing a mask and keeping social distancing is a better 
approach than isolation. 
  
Our recommendations for future research also include improved clearer reporting of methods, 
sampling frames, case definition of asymptomatic, extent of contact tracing, duration of follow-up 
periods, presentation of age distribution of asymptomatic cases and separation of mild cases from 
asymptomatics in result tables. A reliable estimate of the proportion of true asymptomatic cases and 
the burden of disease is imperative in our understanding of infection transmission capacity of 
asymptomatic cases. Until we have the immunological and epidemiological evidence, we advise that 
the importance of asymptomatic cases for driving the spread of pandemic to be considered with 
caution. 
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